Bij de ziekte van Alzheimer treedt neuronale schade op. Veel van de nog niet verklaarde kenmerken van AD lijken verband te houden met afwijkingen aan de signaal functie van insuline. Is AD misschien een complexe neuro-endocriene aandoeining? Kunnen we het risico op AD verlagen door insulinespiegels te bewaken?
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Figuren
Verschenen in
Referenties
Rönnemaa E, Zethelius B, Sundelöf j , et al. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008;71:1065-1071.
Steen E, Terry BM, Rivera EJ. et al. Impaired insulin and insulin-like growth Factor expression and signaling mechanisms in Alzheimers disease — is this
type 3 diabetes J Alzheimers Dis 2005;7;63-80.
Ott A, Stolk RP, van Harskanip F, ec al. Diabetes Mellitus and the risk of dementia: The Rotterdam Study Neurology 1999:53; 1937-1942.
Dankner R, Geulayov G, Olmer L, Kaplan G. Undetected type 2 diabetes in older adults. Age
Ageing 2009; 38:56-62
Beydoun MA, Lhotsky A, Wang Y, et al. Association of adiposity status and changes in early to mid adulthood with incidence of Alzheimer's disease. Am J Epidemial 2008;168:l 179-1189.
Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007:64:93-96.
Vilalta-Franch j , López-Pousa S, Garre-Olmo J, et al, Metabolic syndrome in Alzheimer's disease:
clinical and developmental influentes. Rev Neurol
2008:46:13-17.
Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth tactor e.tpression ond function deteriorate with progression of Alzheimers disease; link to brain reductions in acetylcholine.J Alzheimers
Dis 2005;8;247-268.
de la Monte SM, long M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in
experimental type 3 diabetes: relevance to Alzheimer's disease.; Alzheimers Dis 2006;10;89-109.
Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol/2004:3:169-178.
Reger MA, Watson GS. Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008:70:440-448.
Craft S, Asthana S.Cook DG.et al. Insulin dose-response effects on memory and plasma
amyloid precursor protein in Alzheimer's disease; interactions with apolipoprotein E genotype. Psychoneuroendocrinology 20003:2S:809-S22.
Peila R, Rodriguez BL, Launer LJ, et al. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies; The Honolulu-Asia Aging Study.
Diabetes 2002:51:1256-1262.
Zhao WQ. Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001; 177:125-134.
Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007:56:384-402.
Westerman MA, Cooper-Blackctcr D, Mariash A, et 29. al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimers disease.
Neurosci 2002;22:1858-1867.
Zhao WQ, De Felice FG, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008;22:246-260.
Gong Y, Chang L, Viola KL, et al. Alzheimer's 32. disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Nati Acad Sei U S A
2003;100:10417-10422.
Rivera EJ. Goldin A, Fulmer N, et al. Insulin and Insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.J Alzheimers Dis 2005:8:247-268.
Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007:13:2832-2836.
Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab 2006:32:403- 414.
Sato T, Shimogaito N, Wu X, et al. Toxic advanced glycation end products (TAGE) theory in
Alzheimer's disease. AmJ Alzheimers Dis Other
Demen 2006;21:197-208.
Valente T, Gella A, Fernandez-Busquers X, et al Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimers disease and diabetes mellitus. Neurobiol Dis 2009;Sep 22 [Epub ahead of print]
Zhu X, Su B, Wang X, er al. Cause of oxidative stress in Alzheimer disease. Cell Mol Life Sci
2007:64:2202-2210.
Takeuchi M, Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des
2008; 14:973-978.
Takeuchi M, Sato T, Takino J, ct al. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 2007:69:1358-1366.
